Venthera is a biotechnology company dedicated to developing innovative therapeutics for the treatment of venous and lymphatic malformations (VM and LM). These conditions are congenital vascular anomalies that manifest at birth and can cause various complications such as pain, bleeding, and impaired function. Patients with VM or LM often experience disfigurement, which can have a significant impact on their psychological and social well-being.

Currently, treatment options are limited to surgical procedures, sclerotherapy, laser treatments, and compressive garments, with no approved pharmacological therapies available. Venthera aims to revolutionize the treatment of VM and LM through their cutting-edge approach. They are developing a topical gel called VT30, which targets the genetic source of these malformations.

By inhibiting the PI3K signaling pathway, VT30 suppresses the abnormal growth and survival of the endothelial cells lining the affected channels. This approach has shown promise in preclinical studies, reducing PI3K signaling and improving cell viability. VT30 is designed for direct delivery to the affected tissues, bypassing the need for systemic administration.

As a result, it can provide targeted treatment by accessing the network of malformed vasculature just beneath the skin. Venthera's commitment to improving the lives of patients with VM and LM is backed by a team of dedicated experts, including their Chief Executive Officer, Chief Medical Officer, and VP of Business Development and Operations. They work closely with a distinguished Clinical Advisory Board, consisting of renowned medical professionals in the field.

Additionally, Venthera is part of the BridgeBio family, a team of experts dedicated to developing transformative medicines for genetic diseases. Venthera's groundbreaking approach has the potential to revolutionize the treatment of VM and LM, offering hope to patients affected by these challenging conditions